• ISBN13: 9781119824671
• Binding: Hardcover
• Subject: N/A
• Publisher: Wiley
• Publisher Imprint: Wiley
• Publication Date: August 26, 2025
• Pages: 600
• Original Price: USD 215.0
• Language: English
• Edition: N/A
• Item Weight: 440 grams
• BISAC Subject(s): Pharmacology, Life Sciences / Biochemistry, and Chemistry / Organic

Understand the nature and applications of peptides with this clear and comprehensive guide

Peptides are signaling molecules comprised of amino acids which play an important role in modulating certain physiological processes. They have a wide range of applications, particularly with respect to biological studies and therapeutical potentials. The explosive growth of peptide science in recent years and the variety of achievements in peptide drug discovery and related areas have made it an important area of study for new researchers and industry professionals.

Peptide Science offers a clear, systematic overview of this burgeoning field and its major applications. Covering the chemistry, the pertinent technologies, and major existing therapies, it provides the tools required to integrate peptide research with virtually any area of research and development. Fully cognizant of the latest technological advances, it's a must-own for anyone looking to understand a vital field of chemistry.

Peptide Science readers will also find: *Through coverage of peptide hit generation technologies from nature, to various display libraries and to modern computational designs *Detailed discussion of therapies for conditions including cancer, diabetes, infectious diseases, and more *A section dedicated to key challenges and future directions in peptide therapeutics

Peptide Science is ideal for industry professionals and researchers in organic chemistry, peptide science/chemistry, protein chemistry, biochemistry, and pharmaceutical sciences.

Fa Liu, PhD, is the CSO of Full-Life Technologies, which centers on targeted alpha-radionuclide therapies. Prior to joining Full-Life, he was the CEO and Co-founder of Focus-X Therapeutics (2020-2022), later acquired by Full-Life. Before founding Focus-X, Dr. Liu headed the Chemistry of Novo Nordisk US sites, and Calibrium LLC (acquired by Novo Nordisk) (2014-2020), and served as a Group Leader at the Eli Lilly Peptide Discovery (2009-2014). Prior to Lilly, Dr. Liu worked at National Cancer Institute as a Staff Scientist (2004-2009). He received his Ph.D. in Synthetic Organic Chemistry from Shanghai Institute of Organic Chemistry in 2004.